Medication Options to Treat Respiratory Syncytial Virus (RSV)

Overview

Respiratory Syncytial Virus (RSV) is a virus that can cause a cold-like respiratory illness. For many people, RSV causes a mild illness that goes away in 1-2 weeks with self-care and over-the-counter medication remedies for symptoms. Some people, however, may develop lower respiratory tract disease from RSV that may lead to hospitalization.

Over-the-Counter Medications

For most people, RSV illness is mild and can be managed with over-the-counter medications, including:

  • Fever- and pain-relievers, such as acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen.
    • Note that aspirin should never be given to children.
    • Always follow dosing instructions for OTC medications and check with the doctor or pharmacists before starting new medications if you have medical conditions such as high blood pressure or are taking other medications.
  • Other non-medication self-care remedies, such as saline nose sprays and use of humidifiers may also provide some symptom relief.

Preventive Medications, Including Vaccines

Vaccines and Immunizations

There are currently three RSV vaccines available in the US:

Arexvy is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in

  • Individuals 60 years of age and older.
  • Individuals age 50 through 59 years who are at increased risk for (LRTD) from RSV.

mResvia is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory synctyial virus (RSV) in

  • Individuals 60 years of age and older.
  • Individuals 18 through 59 years of age who are at increased risk of LRTD caused by RSV.

Abrysvo is a vaccine indicated for

  • Pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and sever LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age
  • The prevention of LRTD caused by RSV in individuals 60 years of age and older
  • The prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk of LRTD caused by RSV

Monoclonal antibodies
There are currently two monoclonal antibody injections for RSV prevention in infants and children:

Clesrovimab: Clesrovimab is an antibody that is given as an injection to prevent RSV lower respiratory tract disease in neonates and infants who are born or entering their first RSV season.

Nirsevimab: Nirsevimab is also an antibody that is given as an injection to neonates and infants who are born or entering their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

It's important to note that while these medications are available for RSV treatment and prevention, they have limitations and may not be suitable for everyone.

As with any medication, it's important to consult with a healthcare professional before starting any treatment for RSV. They can provide personalized advice based on an individual's specific medical history and needs. Additionally, they can discuss potential side effects, precautions, and any other relevant information related to these medications or other treatment options for RSV.

What are the potential side effects of Ribavirin and how can they be managed?

Is Palivizumab suitable for my child and what precautions should be taken during its administration?

Are there any other treatment options for RSV apart from Ribavirin and Palivizumab?